These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18759248)

  • 1. An efficient method for accommodating potentially underpowered primary endpoints.
    Li J; Mehrotra DV
    Stat Med; 2008 Nov; 27(26):5377-91. PubMed ID: 18759248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchical testing of multiple endpoints in group-sequential trials.
    Glimm E; Maurer W; Bretz F
    Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
    Huque MF; Alosh M
    J Biopharm Stat; 2012; 22(1):160-79. PubMed ID: 22204533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gatekeeping testing via adaptive alpha allocation.
    Li JD; Mehrotra DV
    Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating co-primary endpoints collectively in clinical trials.
    Li QH
    Biom J; 2009 Feb; 51(1):137-45. PubMed ID: 19219905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A consistency-adjusted alpha-adaptive strategy for sequential testing.
    Alosh M; Huque MF
    Stat Med; 2010 Jul; 29(15):1559-71. PubMed ID: 20552571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method of balanced adjustment in testing co-primary endpoints.
    Kordzakhia G; Siddiqui O; Huque MF
    Stat Med; 2010 Aug; 29(19):2055-66. PubMed ID: 20683896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reviewer's perspective on multiple endpoint issues in clinical trials.
    Huque MF; Sankoh AJ
    J Biopharm Stat; 1997 Nov; 7(4):545-64. PubMed ID: 9358328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constructing multiple test procedures for partially ordered hypothesis sets.
    Edwards D; Madsen J
    Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing surrogates as trial endpoints using mixed models.
    Korn EL; Albert PS; McShane LM
    Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
    Huque MF; Alosh M; Bhore R
    J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The issue of multiplicity in noninferiority studies.
    Ke C; Ding B; Jiang Q; Snapinn SM
    Clin Trials; 2012 Dec; 9(6):730-5. PubMed ID: 22879575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
    Quan H; Luo X; Capizzi T
    Stat Med; 2005 Jul; 24(14):2151-70. PubMed ID: 15909290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.